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Parasympathetic Blockade Attenuates Augmented
Pancreatic Polypeptide But Not Insulin Secretion in
Pima Indians
Barbora Vozarova de Courten,1 Christian Weyer,1 Norbert Stefan,1 Mark Horton,2 Angelo DelParigi,1
Peter Havel,3 Clifton Bogardus,1 and P. Antonio Tataranni1
There is evidence from animal models of obesity and
type 2 diabetes that increased parasympathetic vagal
input to the pancreas contributes to hyperinsulinemia.
Compared with Caucasians, Pima Indians have a high
risk of type 2 diabetes and exhibit marked hyperinsu-
linemia and elevated plasma levels of pancreatic
polypeptide (PP), an islet hormone considered a surro-
gate marker of parasympathetic nervous system (PNS)
drive to the pancreas. To test if hyperinsulinemia in
Pima Indians is due to increased vagal input to the
-cell, we examined the effect of PNS blockade in 17
Caucasian (aged 35 8 years, body fat 23 7% [mean
SD]) and 17 Pima Indian males (aged 28  8 years, body
fat 29  5%) with normal glucose tolerance. Each
participant underwent four consecutive standardized
liquid meal tests (64% carbohydrate, 22% fat, and 14%
protein) during which a primed infusion of atropine was
administered for 120 min at the following doses: 0, 2.5,
5, and 10 g  kg fat-free mass (FFM)1  h1. Areas
under the curve for early (AUC0–30 min) and total
(AUC
0–120 min
) postprandial insulin and PP secretory re-
sponses were calculated. Early postprandial insulin and
PP secretory responses were higher in Pima Indians
compared with those of Caucasians (both P  0.01).
Secretion of insulin and PP was inhibited by atropine
(both P < 0.001). Increasing doses of atropine attenu-
ated the ethnic difference in PP (P  0.01) but not in
early insulin secretory responses (P  0.6), an effect
that was not due to differences in gastric emptying rate
(acetaminophen test) and/or circulating glucose. Simi-
lar results were observed for total secretory responses.
These results confirm that compared with Caucasians,
Pima Indians have an exaggerated PNS drive to pancre-
atic F-cells that secrete PP. However, the hyperinsulin-
emia of this population does not appear to be due to
increased vagal input to pancreatic -cells. Diabetes 53:
663–671, 2004
The Pima Indians of Arizona have one of thehighest reported prevalence rates of obesity andtype 2 diabetes in the world (1). Compared withCaucasians, Pima Indians have, on average,
lower insulin sensitivity and higher plasma insulin concen-
trations, both fasting and in response to intravenous and
oral glucose loads (2). Prospectively, fasting hyperinsulin-
emia predicts the development of diabetes in both Pima
Indians (3–5) and other populations (6,7). The hyperinsu-
linemia in Pima Indians appears to be an early character-
istic because Pima Indian children have 50–70% higher
fasting insulin concentrations than Caucasian children (8).
The precise mechanisms contributing to hyperinsulin-
emia in Pima Indians remain unknown. In part, the higher
fasting insulin concentrations may be a secondary adapta-
tion of the -cell to compensate for the high degree of
insulin resistance. However, the latter does not appear to
entirely account for the hyperinsulinemia (2).
Hyperinsulinemia is also an early feature of various
animal models of both genetic and hypothalamic obesity
and type 2 diabetes, such as the ob/ob mouse (9), the fa/fa
rat (10), and rodents with lesions of the ventromedial
hypothalamus (11,12). In these animals, the hyperinsulin-
emia is thought to be due in large part to an exaggerated
parasympathetic drive to the pancreatic -cells because
acute administration of parasympathicolytic drugs such as
atropine (a blocker of muscarinic receptors) (9–11) or
truncal vagotomy (12,13) can almost completely normalize
insulin levels.
Compared with Caucasians, Pima Indians have been
reported to have higher plasma concentrations of pancre-
atic polypeptide (PP) both in the fasting state and espe-
cially in response to a meal (14,15). PP is a peptide
hormone produced by the pancreatic F-cells, the secretion
of which is largely under vagal control (16). In response to
a meal, plasma PP concentrations increase, in parallel to
an increase in plasma insulin concentrations (15,17). Va-
gotomy (17) or administration of parasympatholytic drugs
such as atropine completely abolish the postprandial
increase in PP in humans (18,19). Conversely, electrical
stimulation of the vagus nerve or administration of para-
sympathicomimetic drugs such as pyridostigmin (a cho-
linesterase inhibitor) increase PP secretion (19,20). Based
on these findings, it is generally agreed that the plasma PP
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concentration represents a valid surrogate marker of the
parasympathetic drive to the pancreas (16).
Based on these findings, we hypothesized that an in-
creased parasympathetic drive to the pancreas might
contribute to hyperinsulinemia in Pima Indians. To test
this hypothesis, we examined the effect of graded doses of
the parasympathetic nervous system (PNS) blocker atro-
pine on postprandial PP and insulin secretory responses in
17 Caucasian and 17 Pima Indian men with normal glucose
tolerance.
RESEARCH DESIGN AND METHODS
Subjects. Seventeen Caucasian and 17 Pima Indian men were admitted for
7–10 days to the metabolic ward of the Clinical Diabetes and Nutrition Section
of the National Institutes of Health in Phoenix, AZ. Women were not studied
to avoid the confounding effects of hormonal changes during the menstrual
cycle. All subjects were between 18 and 50 years of age, normal glucose
tolerant according to a 75-g oral glucose tolerance test (World Health
Organization 1985 criteria) (21), nonsmokers at the time of the study, and,
except for obesity, healthy according to a physical examination and routine
laboratory tests. None were taking medications at the time of entry into the
study. The protocol was approved by the Institutional Review Boards of the
National Institute of Diabetes and Digestive and Kidney Diseases and the
Phoenix area. All subjects provided written informed consent before partici-
pation.
Methods and experimental protocol. Subjects were admitted for 8–10 days
to the National Institutes of Health Clinical Research Unit in Phoenix, AZ,
were fed a weight-maintaining diet (50, 30, and 20% of daily calories provided
as carbohydrate, fat, and protein, respectively), and abstained from strenuous
exercise.
Body composition was estimated by total body dual-energy X-ray absorp-
tiometry (DPX-L; Lunar Radiation, Madison, WI) with calculations of percent-
age of body fat, fat mass, and fat-free mass (FFM) as previously described
(22).
At least 3 days after admission and after a 12-h overnight fast, subjects
underwent a 2-h 75-g oral glucose tolerance test. Plasma glucose concentra-
tions were determined by the glucose oxidase method (Beckman Instruments,
Fullerton, CA) and plasma insulin concentrations by an automated immuno-
assay (Access; Beckman Instruments).
On day 3, before administration of atropine, subjects underwent a series of
four standard tests for the assessment of cardiovascular autonomic nervous
system activity (23). During these tests, subjects were in a sitting position and
blood pressure and electrocardiogram were monitored continuously. In the
first two tests, which assessed PNS activity, the change in heart rate was
assessed in response to deep breathing (the difference between minimum and
maximum heart rate during six deep breathing cycles per min) and a Valsalva
maneuver (the ratio of the longest R-R interval after the maneuver to the
shortest R-R interval during the maneuver). In the third and fourth tests,
which assessed sympathetic nervous system activity, the change in blood
pressure was measured in response to standing up (the difference between the
lowest systolic pressure in the first 2 min after standing up and the average
systolic pressure while lying down) and in response to a hand-grip test (using
a dynamometer, 30% of maximum voluntary contraction over 5 min).
On 4 separate days after a 12-h overnight fast, subjects were fed a
standardized liquid meal (Ensure Plus, 20% of daily caloric requirements [64%
carbohydrate, 22% fat, and 14% protein, identical on all 4 days]) (Fig. 1). The
room was maintained at mesopic illumination levels, and the volunteer was
instructed to abstain from near-centered visual tasks. During each test, two
intravenous catheters were placed in an antecubital vein on the left and right
arm, one for the saline/atropine infusion and one for blood sampling. After a
30-min baseline period, a primed-continuous infusion of the study medication
was started and maintained for 150 min. To avoid the risk of untoward effects
of high-dose atropine in hypersensitive individuals, infusions were not ran-
domized. The infusions contained saline on the first occasion, always followed
by three increasing doses of atropine. Atropine was administered in doses of
2.5, 5, or 10 g/kg FFM for priming (injected over 2 min), followed by a
continuous infusion at doses of 2.5, 5, or 10 g  kg FFM1  h1, respectively.
At 0 min, subjects ingested the standardized liquid meal within 5 min. Since
atropine was shown to affect gastrointestinal motility, we estimated the rate of
gastric emptying by use of the acetaminophen absorption test (24,25). For this
FIG. 1. Study design. Subjects admitted to the Clinical Research Unit first underwent a series of four standard autonomic nervous system (ANS)
tests and a 75-g oral glucose tolerance test (OGTT). Then, on 4 separate days, four atropine infusion studies were conducted. In each of the
studies, after 30 min baseline, an atropine infusion was administered at the following doses: 0, 2.5, 5 and 10 g  kg FFM1  h1 and continued
until the end of the experiment. At 60 min (30 min after the start of atropine administration), a liquid meal test was administered. Plasma PP,
insulin, glucose, acetaminophen, blood pressure, and heart rate were measured throughout the experiment. DEXA, dual-energy X-ray
absorptiometry.
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purpose, the liquid meal contained 20 mg/kg of acetaminophen, the appear-
ance of which in the plasma was determined at subsequent time points (60,
30, 60, and 120 min). Blood pressure, heart rate, and electrocardiogram were
monitored continuously throughout the experiment and documented at the
same time points as the blood samples, and they were collected to measure
PP, insulin, and glucose (60, 45, 30, 20, 0, 5, 10, 15, 20, 30, 45, 60, and
120 min). Plasma PP concentrations were determined by a radioimmunoassay
(Linco, St. Charles, MO). The within and between errors in this assay were 7
and 10%, respectively. Immediately before, immediately after, and 30 min after
injection of the priming dose (2 min) of saline or atropine, ocular responses
were examined by a pupillometer (Iscan, Burlington, MA), which allowed us
to measure the pupil area and the near point of accommodation.
Statistical analyses. Statistical analyses were performed using the software
of the SAS Institute (Cary, NC). Results are given as means  SD unless
indicated otherwise. The values for plasma insulin were logarithmically
transformed before analysis to approximate normal distributions.
Racial differences in autonomic nervous system tests were assessed by
unpaired t test. ANOVA for repeated measures was used to assess the effect of
race and intervention (to exclude possible carryover effects of consecutive
atropine studies) on fasting plasma insulin, glucose, and PP concentrations at
baseline (60 to 30 min of the study) and during infusion of atropine (30
to 0 min).
Areas under the curve (AUC) for early (AUC0–30 min) and total (AUC0–120
min) plasma insulin, glucose, PP, and acetaminophen were calculated using the
trapezoid method. To account for differences in peripheral glucose uptake and
any residual effect of gastric emptying rate not captured by the acetaminophen
test and racial differences in percentage of body fat, all time points for insulin
and glucose of all four atropine studies were used to adjust plasma insulin for
plasma glucose. AUCs for early (AUC0–30 min) and total (AUC0–120 min) adjusted
plasma insulin secretory responses were then calculated. ANOVA for repeated
measures was used to assess the effects of race and intervention and the
interaction between race  intervention on secretory responses for plasma
insulin, glucose, PP, and acetaminophen. The race effect within each atropine
study was assessed post hoc by unpaired t test. The effect of atropine on blood
pressure, heart rate, pupillometry, and near point of accommodation was
similarly assessed by ANOVA.
RESULTS
The anthropometric and metabolic characteristics of the
study populations are summarized in Table 1. Pima Indi-
ans were younger and shorter and had a slightly higher
body fat content than Caucasians (Table 1). There were no
differences in heart rate in response to deep breathing
(P  0.9), prolongation of R-R interval in response to
Valsalva maneuver (P  0.6), or decrease of systolic blood
pressure in response to standing up (P  0.4) between
Pima Indians and Caucasians (Table 2). Diastolic blood
pressure in response to the hand-grip test increased more
in Pima Indians than in Caucasians (P  0.04) (Table 2).
There was no correlation between fasting PP and any of
the measurement of cardiovascular autonomic nervous
system activity (r  0.31, P  0.2 for the change in heart
rate, r  0.05, P  0.8 for ratio of maximal and minimal
R-R interval, r  0.15, P  0.5 for change in systolic
blood pressure in response to standing up, and r  0.18,
P  0.4 for change in diastolic blood pressure in response
to hand-grip trip). There was no correlation between
fasting insulin and any of the measurements of PNS
activity (r  0.05, P  0.8 for the change in heart rate,
and r0.31, P 0.2 for ratio of maximal to minimal R-R
interval).
Effect of PNS blockade on plasma insulin, glucose,
and PP
Fasting plasma insulin, glucose, and PP. Mean
plasma insulin, glucose, and PP during the baseline period
before atropine administration (60 to 30 min) did not
differ between Pima Indians and Caucasians on any of the
study days (all P  0.3).
Fasting plasma insulin and PP concentrations decreased
(both P  0.0001 for intervention effect), whereas fasting
plasma glucose concentration did not change with increas-
ing dose of atropine (P  0.5). Fasting plasma insulin, PP,
and glucose concentrations during the atropine infusions
but before consumption of the meal did not differ between
Pima Indians and Caucasians (all P 0.05, for race effect),
and there were no differences in response to atropine
between Pima Indians and Caucasians (P 0.9 for insulin,
P  0.06 for PP, and P  0.5 for glucose and for race 
intervention effect).
Postprandial changes of plasma insulin, glucose,
PP, and acetaminophen. The time course of the change
of plasma PP, insulin, and glucose in response to the meal
at all doses of atropine for both Pima Indians and Cauca-
sians is shown in Fig. 2.
Plasma acetaminophen AUC (AUC0–120 min) decreased
with increasing atropine (P  0.0001), but there was no
difference in response to atropine administration between
Pima Indians and Caucasians (P  0.9) (Fig. 3A). As
expected, overall there was a positive association between
plasma acetaminophen and glucose concentrations (r 
0.56, P  0.0001). Nevertheless, because plasma glucose
TABLE 1
Baseline physical and metabolic characteristics of 17 Pima
Indians and 17 Caucasians
Pima Indians Caucasians
n (men) 17 17
Age (years) 28 8 35  8*
Height (cm) 171 3 178  7†
Body weight (kg) 96 29 93  24
Body fat (%) 29 5 23  7
Waist-to-thigh ratio 1.63 0.11 1.63 0.17
Fasting plasma glucose (mg/dl) 89 5 87  6
2-h plasma glucose (mmol/l) 103 17 106 23
Fasting plasma insulin (U/ml) 27 8 25  8
Fasting PP (pg/ml) 79 39 69  30
Systolic blood pressure
(mmHg) 124 9 120  10
Diastolic blood pressure
(mmHg) 77 6 75  7
Heart rate (bpm) 63 11 62  7
Data are means  SD. Symbols indicate significant differences
between Pima Indians and Caucasians (unpaired t test): *P  0.05;
†P  0.01.
TABLE 2
Autonomic nervous system test results in 17 Pima Indians and 17
Caucasians
Pima Indians Caucasians
Change in the heart rate during
deep breathing (bpm) 9 4 9 2
Ratio of maximum to minimum R-R
interval 1.4 0.1 1.4  0.1
Change in systolic blood pressure
between standing up and supine
(mmHg) 12  7 9  8
Change in diastolic blood pressure
between hand grip and resting
(mmHg) 19 10 9  7*
*Significant differences between Pima Indians and Caucasians (un-
paired t test), P  0.05.
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concentrations after a meal vary not only in relation to
gastric emptying rate but also to the rate of peripheral
tissue uptake (Fig. 2), plasma insulin responses were
adjusted for plasma glucose levels to account for this
effect (Fig. 3B).
Total postprandial PP secretion during the placebo
infusion were 2.1-fold higher in Pima Indians than Cauca-
sians (P  0.02) and decreased with increasing doses of
atropine (P  0.0001). The decrease in total PP secretory
responses was greater in Pima Indians than Caucasians
(P  0.02, for race  intervention effect). Total postpran-
dial insulin responses (AUC0–120 min) tended to be higher in
Pima Indians compared with Caucasians (2.9-fold, P 
0.06) and decreased with increasing doses of atropine
(P  0.001), but there was no difference in overall re-
sponse to atropine between Pima Indians and Caucasians
(P  0.6). The total postprandial glucose AUC was similar
in Pima Indians and Caucasians (P  0.7) and decreased
with increasing atropine (P  0.001), and there was no
difference in response to atropine between Pima Indians
FIG. 2. Time course of plasma insulin (A), glucose (B), and PP (C) with SEs during the four interventions (atropine studies [ARs]), i.e., AR1 study
(placebo, full line), AR2 (dose 2.5 g  kg FFM1  h1, dashed line), AR3 (dose 5 g  kg FFM1  h1, dotted dashed line), and AR4 (dose 10 g
 kg FFM1  h1, dotted line).
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and Caucasians (P  0.5, Fig. 2). The mean adjusted
insulin AUC was larger in Pima Indians than in Caucasians
(P  0.03) and decreased with increasing atropine dose
(P  0.01), and there was no difference in response to
atropine between Pima Indians and Caucasians (P  0.6).
There was no correlation between overall postprandial PP
response and acetaminophen concentrations during the
four interventions (r  0.05, P  0.2).
Early postprandial adjusted insulin and PP secretory
responses (AUC0–30 min) were 2.5-fold and 2-fold higher in
Pima Indians compared with Caucasians, respectively
(Fig. 4). Secretion of adjusted insulin and PP was dose-
dependently inhibited by atropine (Fig. 4). Increasing
doses of atropine attenuated the ethnic difference in PP
but not in adjusted insulin responses (Fig. 4).
Effect of PNS blockade on blood pressure, heart rate,
and pupillometry. Baseline systolic and diastolic blood
pressure and heart rate during baseline did not differ
between Pima Indians and Caucasians and the atropine
studies (all P  0.4) (Fig. 5).
Systolic and diastolic blood pressure during the atropine
infusion increased with increasing dose of atropine (all
P  0.001 for intervention effect), but did not differ
between Pima Indians and Caucasians (both P  0.2), and
there was no difference in response to atropine between
Pima Indians and Caucasians (all P  0.2).
FIG. 3. A: The dose-response effect for total postprandial plasma acetaminophen areas under the curve (AUCs0–120 min) during four interventions
in Pima Indians and Caucasians. B: Relationship between log plasma insulin and glucose for all of the points and all four atropine studies for Pima
Indians and Caucasians.
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Systolic and diastolic blood pressure AUCs (AUC0–120 min)
in response to meal ingestion did not change with increas-
ing doses of atropine and did not differ between Pima
Indians and Caucasians, and there was no difference in
response to atropine between Pima Indians and Cauca-
sians (P  0.9.). Heart rate AUC in response to the meal
ingestion (AUC 0–120 min) increased with increasing dose of
atropine (P  0.001) and was higher in Pima Indians than
in Caucasians (P 0.02), and there was a greater response
to atropine in Caucasians than in Pima Indians (P  0.04).
There was no effect of race or intervention on the pupil
size or near point of accommodation (all P  0.1).
DISCUSSION
We hypothesized that an increased PNS input to the
pancreas contributes to hypersecretion of insulin and
hyperinsulinemia of Pima Indians. We reasoned that if our
hypothesis was correct then a graded infusion of the PNS
blocker atropine should mitigate the ethnic differences in
PP and in insulin secretion in response to meal ingestion.
We found that PNS blockade abolished the ethnic differ-
ence in plasma PP but not in insulin secretory responses,
suggesting that an increased PNS input of the -cells is not
the primary cause of hyperinsulinemia in Pima Indians.
What is the significance of hyperinsulinemia in Pima
Indians? We have shown that the variability in fasting
plasma insulin concentrations is only partially (	55%)
explained by the difference in insulin sensitivity (2) and
that “relative” hyperinsulinemia in Pima Indians with
normal glucose tolerance is an independent predictor of
type 2 diabetes, probably due to a deleterious effect on
insulin secretion (5). Hyperinsulinemia is also an indepen-
dent risk factor for cardiovascular disease (26) and may
increase the risk of Alzheimer’s disease (27).
Consistent with previous reports (14), we found that
Pima Indians had larger postprandial plasma PP responses
than Caucasians. As expected, increasing doses of atro-
pine led to a dose-dependent reduction of the postprandial
increase of PP. Finally, the highest dose of atropine
completely abolished the postprandial increase of PP, an
effect that was observed in previous studies (17–19,28–30)
of other populations. Unlike previous reports, we did not
observe higher fasting plasma PP levels in Pima Indians
than in Caucasians. This may be due to the relatively small
sample size in the present study. Interestingly, muscarinic
blockade tended to produce a more marked dose-depen-
dent decrease in fasting plasma PP levels in Pima Indians
than in Caucasians.
Hyperinsulinemia in Pima Indians is most pronounced
during the first 30 min of a meal (2). In the present study,
we showed higher early postprandial insulin secretion and
a trend for higher total postprandial insulin secretion in
Pima Indians compared with Caucasians. Both early post-
prandial insulin and total postprandial insulin secretion
were inhibited by increasing doses of atropine. The signif-
icant contribution of the PNS to insulin secretion in
response to meal ingestion has been demonstrated in both
animals (28,30) and humans (29,31). Despite the ethnic
difference, insulin secretion, and the decrease in plasma
insulin response with increasing doses of atropine, there
was no ethnic difference in the ability of cholinergic
blockade to reduce postprandial insulin secretion. Thus,
while the lowest dose of atropine normalized the PP
response in Pima Indians to the magnitude measured
during saline administration in Caucasians, this same dose
did not appreciably reduce the difference in insulin secre-
tion between Pima Indians and Caucasians. Furthermore,
with PP completely suppressed at the highest dose of
FIG. 4. The dose-response effect for early postprandial areas under the curve (AUCs0–30 min) for plasma PP and adjusted insulin (for glucose and
percentage of body fat) during four interventions in Pima Indians and Caucasians. ANOVA for repeated measures was used to assess the effect
of race and intervention and the interaction between race  intervention on secretory responses for early plasma insulin and PP. The race effect
within each atropine study was assessed post hoc by unpaired t test.
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atropine, insulin secretion was still present and was still
significantly higher in the Pima Indians than in Caucasians.
Taken together, these data suggest that PNS contributes to
an increase of plasma insulin secretion in response to a
meal; however, the enhanced insulin secretion in adult
Pima Indians is not due to an exaggerated PNS stimulation
of the -cells.
There are some limitations to our study. First, we did
not achieve a complete blockade of PNS activation by
atropine, which antagonizes only cholinergic muscarinic
receptors but not the release or actions of other PNS-
signaling neuropeptides (26). However, it was shown that
nicotinic blockade provides only a further 9% decrease in
insulin secretion compared with muscarinic blockade
(28). A second limitation is that we did not have a more
accurate measure of insulin sensitivity (i.e., glucose up-
take measured by euglycemic clamp) available in our
study than glucose and percentage of body fat to adjust
FIG. 5. Time course of systolic and diastolic blood pressure and heart rate with SEs during the four interventions (atropine studies [AR]), i.e.,
AR1 study (placebo, full line), AR2 (dose 2.5 g  kg FFM1  h1, dashed line), AR3 (dose 5 g  kg FFM1  h1, dotted dashed line), and AR4
(dose 10 g  kg FFM1  h1, dotted line).
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plasma insulin and thereby account for ethnic differences
in insulin sensitivity. It could be argued that Pima Indians
did not decrease their postprandial plasma insulin more
than Caucasians because they are more insulin resistant.
Finally, we do not have estimates of insulin clearance in
this study. However, in previous studies insulin clearance
was not found to be different in Pima Indians compared
with Caucasians (2) and the effect of atropine on C-peptide
paralleled the effects on insulin, suggesting that insulin
secretion and insulin clearance are not differentially af-
fected by PNS blockade (29).
There are data to suggest that PNS input contributes
directly to enhanced insulin secretion of obesity in young
animals (obese Zucker rats), but that in older animals with
established obesity the primary contributor to hyperinsu-
linemia is increased -cell mass (10). This suggests the
possibility of a hyperstimulation of the pancreas by the
PNS chronically leading to an increase in -cell mass that
may no longer be acutely affected by pharmacological
blockade once established. To our knowledge, no studies
have addressed this possibility.
If an increased PNS drive to the pancreas does not
explain the hyperinsulinemia of Pima Indians then the
question arises of what other hormones might contribute
to this ethnic difference. In this respect, it should be
pointed out that incretins (glucagon-like peptide 1 and
gastric inhibitory peptide) and catecholamines play an
important role in the modulation of postprandial insulin
secretion (28–31). Other possible etiologic factors contrib-
uting to hyperinsulinemia in Pima Indians may include
downregulation of insulin receptors in pancreatic -cells
leading to impaired glucose sensing, plasma free fatty acid
concentrations, -cell insulin receptor expression, meta-
bolic clearance rate of insulin, and abnormalities in central
(hypothalamic) regulatory pathways (5). However, the
contribution of these mechanisms was not addressed this
study.
Despite an ethnic difference in the PNS input to the
pancreatic F-cells, there was no ethnic difference in mea-
sures of PNS activity to other organs (e.g., stomach, eye, or
cardiovascular system). This suggests that PNS activity is
not globally upregulated in Pima Indians compared with
Caucasians. It is well established that PNS outflow is
selective to different tissues and that the input to PNS-
innervated organs is discretely activated under differing
physiological conditions (32). Therefore, it is not too
surprising that activation of the parasympathetic input to
pancreatic F-cells can be exaggerated in response to meal
ingestion in Pima Indians compared with Caucasians but
that PNS activity to other organs or under other conditions
is not exaggerated. Furthermore, the results of this study
indicating increased cholinergic stimulation to PP-secret-
ing F-cells but not to B-cells in Pima Indians provides
evidence that there are likely additional differences in the
PNS input to different cell types within an individual
organ. Whether this cell-specific difference within the islet
is anatomical (i.e., more parasympathetic nerve fibers
adjacent to F-cells than -cells), or functional, with en-
hanced F-cell sensitivity to acetylcholine, is not known.
In conclusion, results from this study confirm that
compared with Caucasians, Pima Indians have an exagger-
ated PNS drive to the pancreas and more specifically to the
pancreatic F-cells. Thus, the hyperinsulinemia of this
population does not appear to be due to increased vagal
input to pancreatic -cells.
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